Skip to main content
. 2018 May 31;58(7):290–295. doi: 10.2176/nmc.ra.2018-0044

Fig. 3.

Fig. 3.

A flow chart showing the relationship between epigenetic changes in DNA, MGMT promoter methylation and response to temozolomide in IDH-mutant gliomas (left side) and diffuse midline gliomas with histone H3K27 mutations (right side).